MX2013007773A - Terapia anticancer con inhibidores duales de aurora quinasa / mek. - Google Patents
Terapia anticancer con inhibidores duales de aurora quinasa / mek.Info
- Publication number
- MX2013007773A MX2013007773A MX2013007773A MX2013007773A MX2013007773A MX 2013007773 A MX2013007773 A MX 2013007773A MX 2013007773 A MX2013007773 A MX 2013007773A MX 2013007773 A MX2013007773 A MX 2013007773A MX 2013007773 A MX2013007773 A MX 2013007773A
- Authority
- MX
- Mexico
- Prior art keywords
- aurora kinase
- mek inhibitors
- anticancer therapy
- dual aurora
- dual
- Prior art date
Links
- 102000003989 Aurora kinases Human genes 0.000 title abstract 2
- 108090000433 Aurora kinases Proteins 0.000 title abstract 2
- 238000011319 anticancer therapy Methods 0.000 title abstract 2
- 239000003719 aurora kinase inhibitor Substances 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 229940124650 anti-cancer therapies Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención describe terapias anti-cáncer que comprenden el uso de inhibidores duales de Aurora quinasa / MEK de acuerdo con lo descrito en la presente memoria.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11150775 | 2011-01-12 | ||
EP11161776 | 2011-04-08 | ||
EP11167688 | 2011-05-26 | ||
PCT/EP2012/050466 WO2012095505A1 (en) | 2011-01-12 | 2012-01-12 | Anticancer therapy with dual aurora kinase / mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013007773A true MX2013007773A (es) | 2013-08-12 |
Family
ID=45463628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013007773A MX2013007773A (es) | 2011-01-12 | 2012-01-12 | Terapia anticancer con inhibidores duales de aurora quinasa / mek. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20130004481A1 (es) |
EP (1) | EP2663303A1 (es) |
JP (1) | JP2014507408A (es) |
KR (1) | KR20140043314A (es) |
CN (1) | CN103429238A (es) |
AR (1) | AR084831A1 (es) |
AU (1) | AU2012206511A1 (es) |
BR (1) | BR112013017671A2 (es) |
CA (1) | CA2824480A1 (es) |
EA (1) | EA201300810A1 (es) |
MX (1) | MX2013007773A (es) |
UY (1) | UY33866A (es) |
WO (1) | WO2012095505A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
EP3246332B1 (en) | 2010-01-12 | 2019-07-10 | Siemens Healthcare Diagnostics Inc. | Oligonucleotides and methods for detecting pik3ca mutations |
EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
BR112012029057A2 (pt) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | composições e métodos de tratamento de leucemia |
US20130122005A1 (en) * | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
RU2713121C2 (ru) | 2012-04-27 | 2020-02-03 | Сайтомкс Терапьютикс, Инк. | Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения |
WO2014009318A1 (en) * | 2012-07-11 | 2014-01-16 | Boehringer Ingelheim International Gmbh | 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer |
JP6320382B2 (ja) | 2012-08-13 | 2018-05-09 | ザ ロックフェラー ユニヴァーシティ | メラノーマの処置および診断 |
PT2892535T (pt) * | 2012-09-04 | 2021-12-15 | Novartis Ag | Método de tratamento adjuvante do cancro |
US20150272952A1 (en) * | 2012-10-22 | 2015-10-01 | Glaxosmithkline Llc | Combination |
JP2015534987A (ja) * | 2012-10-22 | 2015-12-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 組合せ |
CA2889530A1 (en) * | 2012-10-25 | 2014-05-01 | Glaxosmithkline Llc | Combination |
US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
MY181085A (en) | 2013-03-21 | 2020-12-17 | Novartis Ag | Combination therapy |
US20160058751A1 (en) * | 2013-03-28 | 2016-03-03 | Cellworks Group, Inc. | Composition and method for treating cancer |
AU2014273946B2 (en) * | 2013-05-30 | 2020-03-12 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
EP3082779B1 (en) * | 2013-12-20 | 2023-06-07 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 mek and erk inhibitors |
WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
FI3698790T3 (fi) * | 2014-02-07 | 2023-06-06 | Verastem Inc | Menetelmiä epänormaalin solukasvun hoitamiseksi |
WO2015131113A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
JP6644717B2 (ja) | 2014-03-14 | 2020-02-12 | ジェネンテック, インコーポレイテッド | 異種ポリペプチドを分泌させるための方法及び組成物 |
WO2015164862A1 (en) * | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
US11186640B2 (en) * | 2014-07-31 | 2021-11-30 | The University Of Western Australia | Method for the identification of immunotherapy-drug combinations using a network approach |
CN104372103B (zh) * | 2014-12-05 | 2017-05-24 | 武汉友芝友医疗科技股份有限公司 | 一种nras基因突变检测试剂盒 |
CA2972076A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
CN105063177A (zh) * | 2015-05-14 | 2015-11-18 | 广州和实生物技术有限公司 | Braf基因多点突变单管快速检测方法及试剂盒 |
JP2018520164A (ja) * | 2015-07-09 | 2018-07-26 | ザ ジャクソン ラボラトリー | プロテアソームインヒビターと組み合わせてmekインヒビターを投与することによりがんを処置する方法 |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
CN107119331A (zh) * | 2017-05-15 | 2017-09-01 | 重庆市肿瘤研究所 | 肿瘤放射治疗毒性基因突变文库的构建方法 |
KR20200041387A (ko) * | 2017-09-08 | 2020-04-21 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
WO2019104062A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
CN108324713B (zh) * | 2018-01-25 | 2020-09-01 | 三峡大学 | 一种烷基吲哚酮衍生物的应用及抗甲状腺肿瘤药物 |
WO2019195959A1 (en) * | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20230201198A1 (en) * | 2020-04-27 | 2023-06-29 | Verastem, Inc. | Methods of treating abnormal cell growth |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
CA2646638A1 (en) | 2006-04-24 | 2007-11-01 | Boehringer Ingelheim International Gmbh | 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors |
EP2167465A1 (en) | 2007-06-12 | 2010-03-31 | Boehringer Ingelheim International GmbH | Indolinone derivatives and their use in treating disease-states such as cancer |
CN101896227A (zh) * | 2007-12-12 | 2010-11-24 | 阿斯利康(瑞典)有限公司 | 包含mek抑制剂和极光激酶抑制剂的组合 |
PE20110213A1 (es) * | 2008-07-29 | 2011-04-16 | Boehringer Ingelheim Int | Derivados de indolinona como inhibidores de quinasa |
-
2012
- 2012-01-05 US US13/343,858 patent/US20130004481A1/en not_active Abandoned
- 2012-01-11 AR ARP120100092A patent/AR084831A1/es unknown
- 2012-01-12 EA EA201300810A patent/EA201300810A1/ru unknown
- 2012-01-12 US US13/978,748 patent/US20140194442A1/en not_active Abandoned
- 2012-01-12 AU AU2012206511A patent/AU2012206511A1/en not_active Abandoned
- 2012-01-12 WO PCT/EP2012/050466 patent/WO2012095505A1/en active Application Filing
- 2012-01-12 UY UY0001033866A patent/UY33866A/es unknown
- 2012-01-12 CN CN2012800130199A patent/CN103429238A/zh active Pending
- 2012-01-12 EP EP12700082.6A patent/EP2663303A1/en not_active Withdrawn
- 2012-01-12 BR BR112013017671A patent/BR112013017671A2/pt not_active Application Discontinuation
- 2012-01-12 JP JP2013548847A patent/JP2014507408A/ja active Pending
- 2012-01-12 CA CA2824480A patent/CA2824480A1/en not_active Abandoned
- 2012-01-12 MX MX2013007773A patent/MX2013007773A/es unknown
- 2012-01-12 KR KR1020137018187A patent/KR20140043314A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2824480A1 (en) | 2012-07-19 |
EP2663303A1 (en) | 2013-11-20 |
BR112013017671A2 (pt) | 2018-09-18 |
WO2012095505A1 (en) | 2012-07-19 |
UY33866A (es) | 2012-07-31 |
EA201300810A1 (ru) | 2014-01-30 |
CN103429238A (zh) | 2013-12-04 |
US20130004481A1 (en) | 2013-01-03 |
AU2012206511A1 (en) | 2013-07-04 |
AR084831A1 (es) | 2013-06-26 |
US20140194442A1 (en) | 2014-07-10 |
KR20140043314A (ko) | 2014-04-09 |
JP2014507408A (ja) | 2014-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013007773A (es) | Terapia anticancer con inhibidores duales de aurora quinasa / mek. | |
PH12017501176A1 (en) | Pyruvate kinase activators for use therapy | |
IL238548A0 (en) | Adjuvant treatment of a kinase inhibitor from the tec family | |
DK3791896T3 (da) | Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling | |
MX355728B (es) | Inhibidores de cinasas. | |
EP3132033A4 (en) | Beta-lactamases with improved properties for therapy | |
EP3210129A4 (en) | Dual mode gaming system with bingo progressive plug-in | |
EP2822558A4 (en) | PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY | |
IN2014DN00180A (es) | ||
EP2994155A4 (en) | Targeting the egfr-sglt1 interaction for cancer therapy | |
EP3053578A4 (en) | Combination cancer therapy using azabicyclo compound | |
EP3256115A4 (en) | COMBINATION CANCER THERAPY | |
EP3267975A4 (en) | Polymer-drug conjugates for combination anticancer therapy | |
PL2748147T3 (pl) | Podstawione 2-alkilo-1-okso-n-fenylo-3-heteroarylo-1,2,3,4- tetrahydroizochinolino-4-karboksamidy do terapii przeciwmalarycznych | |
EP3220920A4 (en) | Combination therapy effective against microorganisms, including drug resistant microorganisms | |
IN2014DN08477A (es) | ||
EP3007704A4 (en) | Combination therapy | |
WO2012106473A3 (en) | Dosing for treatment with anti-egfl7 antibodies | |
WO2014188201A3 (en) | Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me | |
EP3280261A4 (en) | Anticancer therapeutic agents | |
MX2015001134A (es) | Compuestos terapeuticos. | |
UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
UA72478U (ru) | Применение полентара как средства фригопротекторного действия | |
AU2012902291A0 (en) | Combination Therapy | |
AU2012900695A0 (en) | Bandbuilder.com |